Bispecific Antibodies in the Treatment of Multiple Myeloma: An Expert Case-Based Discussion

Centering discussion on several patient cases, expert panelists review key updates in the use of bispecific antibodies to manage multiple myeloma.

EP. 1: Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab

December 29th 2022

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

EP. 2: Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

December 29th 2022

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

EP. 3: Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

January 5th 2023

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

EP. 4: BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS

January 5th 2023

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

EP. 5: BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections

January 12th 2023

Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.

EP. 6: Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab

January 12th 2023

Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.

EP. 7: Appropriate Patient Selection for Talquetamab in Relapsed/Refractory MM

January 19th 2023

Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.

EP. 8: Patient Case 3: Cevostamab in a Patient with MM who Progressed on Multiple Lines of Therapy

January 19th 2023

Centering discussion on the final patient case, experts review the case of a patient with relapsed/refractory multiple myeloma managed with FcRH5-targeting bispecific cevostamab.

EP. 9: Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM

January 26th 2023

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

EP. 10: Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives

January 26th 2023

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.